Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Emily B. Dunkelberger"'
Autor:
Angelo D’Alessandro, Kang Le, Maureen Lundt, Quan Li, Emily B. Dunkelberger, Troy Cellmer, Andrew J. Worth, Spurthi Patil, Chris Huston, Abby Grier, Monika Dzieciatkowska, Daniel Stephenson, William A. Eaton, Swee Lay Thein
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Mitapivat, a pyruvate kinase (PK) activator, shows great potential as a sickle cell disease (SCD)- modifying therapy. Safety and efficacy of mitapivat as a long-term maintenance therapy is currently being evaluated in two open-label studies. Here we
Externí odkaz:
https://doaj.org/article/d5325d01dfa842ca8f03f72430be3114
Autor:
Xunde Wang, Yi-Ping Fu, Quan Li, Emily B Dunkelberger, Mickias Tegegn, Penelope A. Kosinski, Heidi Mangus, John Hamre, Sam M. Mbulaiteye, Ludmila Prokunina-Olsson, Stephen J. Chanock, Nancy Asomaning, Neal Jeffries, William Eaton, Swee Lay Thein
Publikováno v:
Blood. 140:954-956
Autor:
Belhu Metaferia, Troy Cellmer, Emily B. Dunkelberger, Quan Li, Eric R. Henry, James Hofrichter, Dwayne Staton, Matthew M. Hsieh, Anna K. Conrey, John F. Tisdale, Arnab K. Chatterjee, Swee Lay Thein, William A. Eaton
Stem-cell transplantation and genetic therapies offer potential cures for patients with sickle cell disease (SCD) but these options require advanced medical facilities and are expensive. Consequently, these treatments will not be available to the vas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cc257e52a2534b8ba20da96f509a6d5
https://doi.org/10.1101/2022.06.23.497377
https://doi.org/10.1101/2022.06.23.497377
Autor:
Maureen Lundt, Nancy Asomaning, Ingrid Frey, Xunde Wang, Anna Conrey, Julia Z Xu, Quan Li, Emily B Dunkelberger, Neal Jeffries, William Eaton, Swee Lay Thein
Publikováno v:
Blood. 140:2508-2509
Autor:
Julia Harper, Eric R. Henry, Swee Lay Thein, Quan Li, William A. Eaton, Emily B. Dunkelberger, Troy Cellmer, H. Franklin Bunn, Kristen E. Glass, Robert B. Best, Belhu B. Metaferia, Anna Conrey
Publikováno v:
Blood. 138(13)
The issue of treating sickle cell disease with drugs that increase hemoglobin oxygen affinity has come to the fore with the US Food and Drug Administration approval in 2019 of voxelotor, the only antisickling drug approved since hydroxyurea in 1998.
Autor:
Pablo Bartolucci, William A. Eaton, Quan Li, Emily B. Dunkelberger, David Ostrowski, Swee Lay Thein, Troy Cellmer, Belhu B. Metaferia, James Hofrichter, John M. Louis, Eric R. Henry, Rodolfo Ghirlando, Frédéric Galactéros, Stéphane Moutereau
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Significance The root cause of pathology in sickle cell disease is the polymerization of the mutant hemoglobin S upon deoxygenation in the tissues to form fibers. Both the amount of fiber at equilibrium and the kinetics of fiber formation depend on t
Publikováno v:
The Journal of Physical Chemistry B. 122:11579-11590
The polymerization of the mutant hemoglobin S upon deoxygenation to form fibers in red blood cells of patients suffering from sickle-cell anemia results in changes in cell shape and rigidity, also known as sickling, which underlie the pathology of th
Autor:
Troy Cellmer, Quan Li, William A. Eaton, Heidi Mangus, Anna Conrey, Laurel A Menapace, Julia Z. Xu, Varsha Iyer, Penelope A. Kosinski, Peter Hawkins, Lenny Dang, Laxminath Tumburu, Charles Kung, Eric R. Henry, James S. Nichols, Swee Lay Thein, Timothy Lequang, Ingrid Frey, Emily B. Dunkelberger, Neal Jeffries
Publikováno v:
Blood. 136:21-22
Background. Sickle cell disease (SCD) is a devastating disorder initiated by polymerization of the deoxy-hemoglobin S (HbS) to form fibers that distort (sickle) erythrocytes. Increased intracellular 2,3- diphosphoglycerate (2,3-DPG) stabilizes fibers
Autor:
Majed Almashjary, Emily B. Dunkelberger, Hans Ackerman, Oswaldo Castro, Steven E. Brooks, William A. Eaton
Publikováno v:
The FASEB Journal. 33
Autor:
Terri H. Wakefield, Eric R. Henry, William A. Eaton, Jeffrey F. Smith, Matthew M. Hsieh, Mary E. Link, Emily B. Dunkelberger, Jeffery L. Miller, James Hofrichter, Troy Cellmer, John F. Tisdale, Dwayne Staton, Belhu B. Metaferia, Garrott W. Christoph, Stacy Jones-Straehle, Quan Li, Sarah Boutom, Erica R. Vass
Publikováno v:
Proceedings of the National Academy of Sciences. 114
Although it has been known for more than 60 years that the cause of sickle cell disease is polymerization of a hemoglobin mutant, hydroxyurea is the only drug approved for treatment by the US Food and Drug Administration. This drug, however, is only